- Home
- FENG vs NCEL Comparison
FENG vs NCEL Comparison
Compare FENG & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENG | NCEL |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | China | Switzerland |
| Employees | N/A | 4 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.8M | 20.6M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENG | NCEL |
|---|---|---|
| Price | $1.64 | $3.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.7K | ★ 32.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $1.83 |
| 52 Week High | $3.65 | $5.12 |
Technical Indicators
Market Signals| Indicator | FENG | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 52.22 |
| Support Level | N/A | $3.03 |
| Resistance Level | $1.82 | $3.54 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.06 | 55.71 |
Price Performance
Historical ComparisonAbout FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.